Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
18 pending office actions • 4 clients • 17 examiners • 12 art units • 0 of 18 (0%) have an AI response strategy ready • 24 patents granted in the last 365 days
BAUMGARTNER PATENT LAW operates within the Biotechnology & Pharmaceuticals sector, managing a total of 671 career applications. The firm currently faces 17 pending office actions. Its resolved allowance rate stands at 74.37 percent, which provides a baseline for its success in securing intellectual property rights in this specialized field. This 74.37 percent rate reflects the firm's historical performance in navigating the complexities of biotech prosecution.
The firm averages 2.66 office actions per allowance, a figure that highlights its typical prosecution cycle length. This 2.66 average suggests a relatively direct path to allowance, potentially indicating efficient communication with the patent office. With 671 career applications, the firm has established a measurable track record. The 17 pending office actions and the 2.66 office actions per allowance together illustrate the current state of the firm's active and historical docket, offering insight into its capacity and effectiveness.
Based on the USPTO statutory response window for each pending office action. 6 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 6 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (11%) |
| §103 only | 6 (33%) |
| Double-patenting + other | 1 (6%) |
| Multi-statute (no §101) | 9 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VIVLEMORE, TRACY ANN | 2 | 73.0% | +6.6% |
| PHILLIPS, FORREST M | 1 | 83.2% | +14.2% |
| CONNORS, ALEXANDRA F | 1 | 23.9% | +45.4% |
| CANDELARIA, JULIANA IRENE | 1 | 0.0% | +0.0% |
| LARA, CAROLINE MONSERRAT | 1 | 100.0% | +0.0% |
| LE, JOHN H | 1 | 87.8% | +6.9% |
| CANNON, RYAN SMITH | 1 | 55.7% | +36.9% |
| DUNN, LINDSAY MICHELLE | 1 | 80.0% | +0.0% |
| NGUYEN, NGHI V | 1 | 53.6% | +50.8% |
| SPENCER, ANDREA LYNNE MORRIS | 1 | 22.2% | +35.7% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18936656 | PREFORMED FACEPIECE CUSHION FOR AN ACOUSTIC MASK AND COMBINATION THEREOF | PHILLIPS, FORREST M | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18300210 | ENHANCEMENT OF CARTILAGE REGENERATIVE ACTIVITY OF STEM CELL POPULATIONS BASED ON REDUCTION OF INTRA-ARTICULAR CELLULAR MATERIAL | KIM, TAEYOON | 161d overdue |
| 18577646 | PHOTOVOLTAIC WINDOW BLIND SYSTEM | CANNON, RYAN SMITH | 23d overdue |
| 18173052 | METHODS FOR QUANTIFYING POTENCY OF REGENERATIVE IMMUNOTHERAPIES | YOUTCHOM PENDIE, EMMANUEL LED | 17d overdue |
| 18785132 | In Vitro and In Vivo Generation of Insulin Producing Cells | CONNORS, ALEXANDRA F | — |
| 18785305 | Orthopedic Regeneration by Inducible Pluripotent Stem Cell Derived Mesenchymal Stem Cells | CANDELARIA, JULIANA IRENE | — |
| 18775133 | Creation of Inducible Pluripotent Stem Cell Derived T Regulatory Cells by In Vitro Recapitulation ofThymic Development | LARA, CAROLINE MONSERRAT | — |
| 18636179 | Three-Dimensional Printing of Organs, Organoids, and Chimeric Immuno-Evasive Organs | LE, JOHN H | — |
| 18483485 | TREATMENT OF DIABETES BY ENHANCEMENT OF PANCREATIC ISLET ENGRAFTMENT THROUGH REGENERATIVE IMMUNE MODULATION | DUNN, LINDSAY MICHELLE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18577646 | PHOTOVOLTAIC WINDOW BLIND SYSTEM | CANNON, RYAN SMITH | 23d overdue |
| 18936656 | PREFORMED FACEPIECE CUSHION FOR AN ACOUSTIC MASK AND COMBINATION THEREOF | PHILLIPS, FORREST M | — |
| 18785132 | In Vitro and In Vivo Generation of Insulin Producing Cells | CONNORS, ALEXANDRA F | — |
| 18363642 | PREVENTION AND TREATMENT OF REPRODUCTIVE FAILURE BY REGENERATIVE CELLS AND ADJUVANTS | NGUYEN, NGHI V | — |
| 18331042 | GENERATION OF CONDITIONED MEDIA FROM INDUCIBLE PLURIPOTENT STEM CELL DERIVED MESENCHYMAL STEM CELLS | SPENCER, ANDREA LYNNE MORRIS | — |
| Client (Assignee) | Pending OAs |
|---|---|
| Creative Medical Technologies | 13 |
| SOLAIRES ENTREPRISES INC. | 3 |
| Talk Systems Inc. | 1 |
| Salyx Medical Inc. | 1 |
| Art Unit | Apps |
|---|---|
| 1631 | 2 |
| 1638 | 2 |
| 2837 | 1 |
| 1726 | 1 |
| 1644 | 1 |
| 1653 | 1 |
| 3794 | 1 |
| 1618 | 1 |
| 1632 | 1 |
| 2859 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18936656 | PREFORMED FACEPIECE CUSHION FOR AN ACOUSTIC MASK AND COMBINATION THEREOF | Talk Systems Inc. | PHILLIPS, FORREST M | 2837 | §103 | Non-Final OA | — | Pending | Nov 04, 2024 |
| 18785132 | In Vitro and In Vivo Generation of Insulin Producing Cells | Creative Medical Technologies, Inc. | CONNORS, ALEXANDRA F | §102§103§112 | Non-Final OA | — | Pending | Jul 26, 2024 | |
| 18785305 | Orthopedic Regeneration by Inducible Pluripotent Stem Cell Derived Mesenchymal Stem Cells | Creative Medical Technologies, Inc. | CANDELARIA, JULIANA IRENE | §101§102§112DP | Non-Final OA | — | Pending | Jul 26, 2024 | |
| 18775133 | Creation of Inducible Pluripotent Stem Cell Derived T Regulatory Cells by In Vitro Recapitulation ofThymic Development | Creative Medical Technologies, Inc. | LARA, CAROLINE MONSERRAT | §102§103§112 | Non-Final OA | — | Pending | Jul 17, 2024 | |
| 18636179 | Three-Dimensional Printing of Organs, Organoids, and Chimeric Immuno-Evasive Organs | Creative Medical Technologies, Inc. | LE, JOHN H | §101§103§112 | Non-Final OA | — | Pending | Apr 15, 2024 | |
| 18577646 | PHOTOVOLTAIC WINDOW BLIND SYSTEM | Solaires Entreprises Inc. | CANNON, RYAN SMITH | 1726 | §102§103§112 | Final Rejection | 23d overdue | Pending | Jan 08, 2024 |
| 18483485 | TREATMENT OF DIABETES BY ENHANCEMENT OF PANCREATIC ISLET ENGRAFTMENT THROUGH REGENERATIVE IMMUNE MODULATION | Creative Medical Technologies, Inc. | DUNN, LINDSAY MICHELLE | 1644 | §103§112 | Non-Final OA | — | Pending | Oct 09, 2023 |
| 18363642 | PREVENTION AND TREATMENT OF REPRODUCTIVE FAILURE BY REGENERATIVE CELLS AND ADJUVANTS | Creative Medical Technologies, Inc. | NGUYEN, NGHI V | 1653 | §102§103§112 | Non-Final OA | — | Pending | Aug 01, 2023 |
| 18331042 | GENERATION OF CONDITIONED MEDIA FROM INDUCIBLE PLURIPOTENT STEM CELL DERIVED MESENCHYMAL STEM CELLS | Creative Medical Technologies, Inc. | SPENCER, ANDREA LYNNE MORRIS | 1631 | §103§112 | Non-Final OA | — | Pending | Jun 07, 2023 |
| 18331098 | INDUCIBLE PLURIPOTENT STEM CELL DERIVED REGENERATIVE T CELLS | Creative Medical Technologies, Inc. | VIVLEMORE, TRACY ANN | 1638 | §102§103§112 | Non-Final OA | — | Pending | Jun 07, 2023 |
| 18325851 | WEARABLE VITAL SIGNS MONITOR AND USE THEREOF | Salyx Medical Inc. | KERN, ASHLEIGH LAUREN | 3794 | §103 | Non-Final OA | 103d overdue | Pending | May 30, 2023 |
| 18315364 | EXOSOME BASED ASSAYS FOR DETERMINING CANDIDATES FOR OSTEOARTHRITIS STEM CELL THERAPY | Creative Medical Technologies, Inc. | CRAIG, KAILA ANGELIQUE | 1618 | §103 | Final Rejection | — | Pending | May 10, 2023 |
| 18311768 | DEGENERATING OVARIAN MICROENVIRONMENT RESISTANT MESENCHYMAL STEM CELLS | Creative Medical Technologies, Inc. | REGLAS, GILLIAN CHELSEA | 1632 | §103§112DP | Final Rejection | — | Pending | May 03, 2023 |
| 18311464 | PROTECTION FROM OVARIAN FAILURE BY LOW DOSE INTERLEUKIN-2 ADMINISTRATION | Creative Medical Technologies, Inc. | VIVLEMORE, TRACY ANN | 1638 | §103 | Non-Final OA | 83d | Pending | May 03, 2023 |
| 18300210 | ENHANCEMENT OF CARTILAGE REGENERATIVE ACTIVITY OF STEM CELL POPULATIONS BASED ON REDUCTION OF INTRA-ARTICULAR CELLULAR MATERIAL | Creative Medical Technologies, Inc. | KIM, TAEYOON | 1631 | §102§103§112 | Non-Final OA | 161d overdue | Pending | Apr 13, 2023 |
| 18181060 | WIRELESS CHARGING SYSTEM FOR LIGHT ELECTRIC VEHICLES | Solaires Entreprises Inc. | INSTONE, NATHANIEL JOSEPH | 2859 | §103 | Non-Final OA | — | Pending | Mar 09, 2023 |
| 18173052 | METHODS FOR QUANTIFYING POTENCY OF REGENERATIVE IMMUNOTHERAPIES | Creative Medical Technologies, Inc. | YOUTCHOM PENDIE, EMMANUEL LED | 1647 | §102§103 | Non-Final OA | 17d overdue | Pending | Feb 22, 2023 |
| 17878804 | SOLAR POWERED ELECTRIC KICK SCOOTER | Solaires Entreprises Inc. | MEDANI, MOHAMED | 3611 | §103 | Final Rejection | 26d | Pending | Aug 01, 2022 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial